Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors Abstract #377

Introduction: Small bowel neuroendocrine tumors (SB NETs) have a reported incidence of approximately 0.5-1 per 100 000 population/yr.
Aim(s): This study analyses the overall survival for patients with SB NET and cause of death over a 25-year period from a single centre.
Materials and methods: A total of 138 patients with SB NETs were identified from the Kings neuroendocrine database. Primary site: Duodenal 2.1% (3), Jejunal 2.9% (4), ileal 95% (131). A total of 623 patient follow-up, with a mean duration of follow-up of five years. Median age: 61 years (range 24-84).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
#376 Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
Introduction: Small bowel neuroendocrine tumors are uncommon tumors with an incidence of <0.5-1 per 100,000 population/year. We report on the survival rates of patients who had the primary tumor resected, to see whether primary tumor removal improves outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#378 Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?
Introduction: Small bowel (SB) NETs are regarded as relatively indolent cancers. ENETS has published TNM staging. This study aims to demonstrate whether the TNM stage predicts survival in this cohort of patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Keywords: TNM, survival